Home > Cardiology > EHRA 2022 > Updates on Ablation > VANISH: Ablation reduces shock burden compared with anti-arrhythmic drug in ventricular tachycardia

VANISH: Ablation reduces shock burden compared with anti-arrhythmic drug in ventricular tachycardia

Presented By
Prof. Michelle Samuel, University of Montreal, Canada
Conference
EHRA 2022
Trial
VANISH
Doi
https://doi.org/10.55788/7f2c35ab
Catheter ablation was associated with a reduced shock-treated ventricular tachycardia (VT) event burden and appropriate shock burden compared with escalated anti-arrhythmic drug (AAD) treatment in patients with AAD-refractory VT who experienced a prior myocardial infarction (MI). The previously published, multicentre, randomised-controlled VANISH trial (NCT00905853) included 259 patients with an implantable cardioverter-defibrillator (ICD) who experienced a prior MI and VT event on AAD treatment in the last 6 months. These patients were randomised to catheter ablation (n=132) or escalated AAD therapy (n=127). After a median follow-up of 23.4 months, the primary composite endpoint of all-cause mortality, VT storm, and appropriate ICD shock favoured ablation over escalated AAD therapy (HR 0.72; P=0.04) [1]. In the current analysis, Prof. Michelle Samuel (Un...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on